ProBioGen has announced Nouscom has activated a commercial product license to ProBioGen's cell-based vaccine platform AGE1.CR.pIX.
ProBioGen's AGE1.CR.pIX cell line was designed for the industrial production of vaccines and viral vectors. The cell line was developed at ProBioGen from primary duck cells, is adapted to suspension-growth and is supplied with with a chemically-defined medium and full documentation.
Elisa Scarselli, CSO of Nouscom said: "Nouscom has recently announced regulatory approval to commence a Phase 1b clinical trial for its personalised cancer neoantigen-vaccine. ProBioGen's AGE1.CR.pIX technology and platform is well suited to enable the rapid manufacture of a component of our uniquely engineered viral vector vaccine."
Dr Volker Sandig, ProBioGen's CSO said: "Nowadays, smart and cost-effective production processes for viral vectors are becoming increasingly important. I am enthusiastic about Nouscom's cutting-edge immunotherapies and I am pleased that we are able to provide them with our sophisticated production platform AGE1.CR.pIX; this shows once again its broad application possibilities."
